Compare

NovaBridge Biosciences/$NBP

1D1W1M3M6MYTD1Y5YMAX

About NovaBridge Biosciences

NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Ticker
$NBP
Sector
Health
Primary listing
NASDAQ
Employees
-

NBP Metrics

BasicAdvanced
$96M
-
-$1.04
1.48
-

What the Analysts think about NBP

Analyst ratings (Buy, Hold, Sell) for NovaBridge Biosciences stock.
Analyst projections of the future price of NovaBridge Biosciences stock.

NBP Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

NBP Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing NBP

Funds
Fund name
Fund size
$NBP weighting
iShares Nasdaq US Biotechnology£BTEK
$1.3B0.01%
iShares Nasdaq US Biotechnology$BTEC
$1.3B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.